title: A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.
abstract: The aim of this study was clarification of the feasibility, effects, and adverse events of combination chemotherapy with paclitaxel and carboplatin in Japanese women with epithelial ovarian cancer. In patients with stage Ic to IV epithelial ovarian cancer, primary cytoreductive surgery was performed. Paclitaxel (175 mg/m(2)) was intravenously infused for 3 h. Subsequently, carboplatin was infused, with an area under the plasma concentration-time curve of 5. Ninety-one patients were enrolled in this study. The mean dose of paclitaxel at the sixth course was 161 mg/m(2). Of 51 patients, a complete response was observed in 19 patients (37%), and a partial response in 23 patients (45%). The response rate for clear cell adenocarcinoma was 25%. With regard to adverse events, grade 4 granulopenia was observed in 80% of patients, suggesting dose-limiting toxicity. However, none of the patients developed serious infection. With regard to non-hematological toxicity, grade 2 or 3 alopecia, arythralgia/myalgia, and peripheral neurotoxicity were noted in 97, 29, and 20% of the patients, respectively. Although hematological toxicity was relatively marked, this regimen can be applied in Japanese women.
authors.affiliation: Department of Obstetrics and Gynecology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi 329-0498, Japan. ytakei@jichi.ac.jp
authors.forename: Yuji
authors.initials: Y
authors.lastname: Takei
authors.forename: Mitsuaki
authors.initials: M
authors.lastname: Suzuki
authors.forename: Michitaka
authors.initials: M
authors.lastname: Ohwada
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Saga
authors.forename: Takahiro
authors.initials: T
authors.lastname: Kohno
authors.forename: Shizuo
authors.initials: S
authors.lastname: Machida
authors.forename: Ikuo
authors.initials: I
authors.lastname: Sato
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018269:Carcinoma, Endometrioid / Q000188:drug therapy / Q000601:surgery; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000601:surgery; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel